» Articles » PMID: 34129628

Autophagy Activity in Cholangiocarcinoma is Associated with Anatomical Localization of the Tumor

Overview
Journal PLoS One
Date 2021 Jun 15
PMID 34129628
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The presence of autophagy has been indicated in cholangiocarcinoma (CC), which disease has poor prognosis and limited treatment options. Recently, CC has been classified by anatomical localization as intrahepatic (iCC), perihilar (pCC) and distal (dCC), showing different clinical and molecular characteristics. Thus, our aim was to compare autophagy activity in CC samples resected from different anatomical locations. Further, we investigated whether autophagy could be modulated in cell lines originated from iCC and extrahepatic CC (eCC) following the treatments with autophagy inhibitory and inducing agents. Tissue microarrays were prepared from 70 CC (28 iCC, 19 pCC and 23 dCC), 31 adjacent non-tumorous and 9 hepatocellular carcinoma (HCC) samples. Autophagy markers LC3, p62 and Beclin1 as well as proliferation marker Ki-67 were monitored by immunohistochemistry and were associated with patients' survival. Modulation of autophagy was investigated in cell lines originated from iCC (HuH-28), eCC (TFK-1) and HCC (HepG2) by treating the cells with chloroquine (CQ) for inhibition and with Rapamycin, 5-Fluorouracil (5-FU) and Sorafenib for induction of autophagy. Our results indicated an inhibited autophagy in iCC and pCC tumor tissues, whereas active autophagy seemed to occur in dCC, especially in samples displaying low Ki-67 index. Additionally, low level of Beclin1 and high level of Ki-67 were associated with poor overall survival in dCC, suggesting the prognostic role of these proteins in dCC. Beside a baseline autophagy detected in each cell line, Rapamycin and 5-FU induced autophagy in iCC and HepG2 cell lines, Sorafenib in iCC cells. A chemotherapy agent in combination with CQ decreased IC50 effectively in the cell lines where basal and/or induced autophagy were present. In conclusion, we revealed differences in the autophagy activities of CC tissues and cell lines originated from different anatomical locations, which might influence patients' treatment. Our results also suggest a prognostic role of Beclin1 and Ki-67 in dCC.

Citing Articles

Autophagy impairment in human bile duct carcinoma cells.

Petrungaro S, de Franchis V, Filippini A, Facchiano A, Gaudio E, Giampietri C Front Physiol. 2023; 14:1249264.

PMID: 37841311 PMC: 10570450. DOI: 10.3389/fphys.2023.1249264.


COTE1 Facilitates Intrahepatic Cholangiocarcinoma Progression via Beclin1-Dependent Autophagy Inhibition.

Zhang H, Chen S, Xu S, Li X Biomed Res Int. 2023; 2023:5491682.

PMID: 37780485 PMC: 10541304. DOI: 10.1155/2023/5491682.


Active Autophagy Is Associated with Favorable Outcome in Patients with Surgically Resected Cholangiocarcinoma.

Bankov K, Schulze F, Gretser S, Reis H, Abedin N, Finkelmeier F Cancers (Basel). 2023; 15(17).

PMID: 37686598 PMC: 10486413. DOI: 10.3390/cancers15174322.


Histone Deacetylase Inhibition and Autophagy Modulation Induces a Synergistic Antiproliferative Effect and Cell Death in Cholangiocarcinoma Cells.

Yenigul M, Gencer Akcok E ACS Omega. 2023; 8(24):21755-21768.

PMID: 37360445 PMC: 10285991. DOI: 10.1021/acsomega.3c01317.


Hydroxychloroquine Induces Apoptosis in Cholangiocarcinoma Reactive Oxygen Species Accumulation Induced by Autophagy Inhibition.

Chen J, Pan Q, Bai Y, Chen X, Zhou Y Front Mol Biosci. 2021; 8:720370.

PMID: 34568426 PMC: 8462510. DOI: 10.3389/fmolb.2021.720370.

References
1.
Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T . Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med. 1995; 177(1):61-71. DOI: 10.1620/tjem.177.61. View

2.
Akkoc Y, Gozuacik D . Autophagy and liver cancer. Turk J Gastroenterol. 2018; 29(3):270-282. PMC: 6284658. DOI: 10.5152/tjg.2018.150318. View

3.
Kimmelman A, White E . Autophagy and Tumor Metabolism. Cell Metab. 2017; 25(5):1037-1043. PMC: 5604466. DOI: 10.1016/j.cmet.2017.04.004. View

4.
Pan T, Wang W, Jia W, Xu G . A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma. Oncol Lett. 2017; 13(5):2957-2964. PMC: 5431743. DOI: 10.3892/ol.2017.5847. View

5.
Wu C, Chen M, Yeh C . mTOR Inhibitors in Advanced Biliary Tract Cancers. Int J Mol Sci. 2019; 20(3). PMC: 6386826. DOI: 10.3390/ijms20030500. View